Therapeutic Pipeline*

TransCode’s initial focus is addressing metastatic breast cancer, followed by other metastatic cancers that have known over-expression of microRNA-10b: pancreatic, prostate, non-small-cell lung, colorectal cancer and others, as well as glioblastoma (see chart below).

In Vitro: TTX-MC138 demonstrated therapeutic efficacy** in vitro in 77% of 624 human tumor cell lines representing the spectrum of metastatic and non-metastatic cancers.

Therapeutic / Target

Discovery
Preclinical
Clinical

TTX-MC138 / microRNA-10b

Metastatic breast cancer

Clinical

Colorectal cancer

Preclinical

NSCL cancer

Preclinical

Pancreatic Cancer***

Preclinical

Glioblastoma***

Clinical

Esophageal cancer***

Preclinical

Ovarian cancer***

Preclinical

 
Lin28b Inhibitor / Lin28b

Pancreatic cancer***

Preclinical

 
anti-microRNA-xxx / microRNA-xxx

Metastasis

Preclinical

 
siRNA / PD-L1

Pancreatic cancer***

Nearing Clinical

*Pipeline currently in development – selected therapeutics and targets may change once funded
**TTX-MC138 demonstrated therapeutic efficacy In Vitro in 77% of 624 human tumor cell lines representing the spectrum of metastatic and non-metastatic cancers. PLOS ONE | https://doi.org/10.1371/journal.pone.0201046 July 2018
***Cancer types classified as orphan diseases